<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04614077</url>
  </required_header>
  <id_info>
    <org_study_id>A2020</org_study_id>
    <nct_id>NCT04614077</nct_id>
  </id_info>
  <brief_title>Vascular Graft Storage Solution Preserves Endothelial Function</brief_title>
  <acronym>VGE</acronym>
  <official_title>Vascular Graft Storage Solution Preserves Endothelial Function</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Klinikum Floridsdorf</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Klinikum Floridsdorf</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Since Saline is still the most widely used storage and flushing solution in cardiovascular&#xD;
      procedures despite knowing evidence of its influence on the human endothelial cell function&#xD;
      the main aim of this study was to assess the effect of DuraGraft©, an intraoperative graft&#xD;
      treatment solution, on human saphenous vein segments 8 Remnants from the operation after&#xD;
      trimming the bypass length), rat aortic segments and human umbilical vein endothelial cells&#xD;
      (HUVECs) in comparison to saline.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Saline is still the most widely used storage and flushing solution in cardiovascular&#xD;
      procedures despite knowing evidence of its influence on the human endothelial cell function.&#xD;
      Aim of this study was to assess the effect of DuraGraft©, an intraoperative graft treatment&#xD;
      solution, on human saphenous vein segments, rat aortic segments and human umbilical vein&#xD;
      endothelial cells (HUVECs) in comparison to saline. According to literature saline could have&#xD;
      detrimental effects on the endothelium but data shows conflicting evidence. Duragraft a so&#xD;
      called endothelial preservation solution should protect the human endothelium. Intent of this&#xD;
      observational study was to study the effects of both solutions and compare them.&#xD;
&#xD;
      Within 12 patients undergoing aortocoronary bypass surgery, left overs from saphenous vein&#xD;
      graft segments were randomized to DuraGraft© (n=12/6) or saline (n=12/6) solution before&#xD;
      intraoperative storage. These segments as well as rat aortic segments underwent assessment of&#xD;
      vascular function in a multichamber isometric myograph system in comparison to&#xD;
      Krebs-Henseleit solution (KHS), a physiologic organ buffer solution. Additionally, human&#xD;
      umbilical vein endothelial cells (HUVECs) were used for cell viability tests.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 1, 2019</start_date>
  <completion_date type="Actual">September 30, 2020</completion_date>
  <primary_completion_date type="Actual">September 30, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>vessel function organ bath assessment</measure>
    <time_frame>3 hours</time_frame>
    <description>defines significant contraction or relaxation between the two solutions, a myograph will be used, every change above 5 nM will be seen as significant.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>cell viability testing</measure>
    <time_frame>60 minutes</time_frame>
    <description>shows significant difference between the two solutions, cell number of living cells will be simply counted and compared between the two solutions using a standard microscope and counting chamber</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">12</enrollment>
  <condition>Vein Injury</condition>
  <arm_group>
    <arm_group_label>A( saline)</arm_group_label>
    <description>The vein piece 1 cm is taken from one patient, then the piece is divided and assigned to saline or the specific solution.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B specific solution</arm_group_label>
    <description>The vein piece 1 cm is taken from one patient, then the piece is divided and assigned to saline or the specific solution.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>ex vivo organ bath testing, preservation of vein sections without contact to patient</intervention_name>
    <description>1 piece of vein is separated during surgical bypass procedure, then randomized and put ex vivo in two solutions: saline and specific solution, then tested in the organ bath</description>
    <arm_group_label>A( saline)</arm_group_label>
    <arm_group_label>B specific solution</arm_group_label>
    <other_name>organ bath ex vivo comparing saline vs specific solution</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        patients undergoing bypass surgery exluding emergency cases&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patient is undergoing isolated CABG procedure or CABG plus aortic or mitral valve&#xD;
             surgery with at least one saphenous vein or radial artery grafts&#xD;
&#xD;
          -  Patient is ≥18 years of age&#xD;
&#xD;
          -  Patient (or a legally authorized representative) is willing and able to provide&#xD;
             consent&#xD;
&#xD;
          -  DuraGraft® is being used for the CABG procedure&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Participation in a device study or receiving active drug product in an investigational&#xD;
             study within one month (30 days) prior to enrollment.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bernhard Winkler, Associate Professor Priv. Doz. DDR.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Klinikum Floridsdorf</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>KH North Vienna</name>
      <address>
        <city>Vienna</city>
        <zip>1230</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
  </location_countries>
  <reference>
    <citation>Santoli E, Di Mattia D, Boldorini R, Mingoli A, Tosoni A, Santoli C. University of Wisconsin solution and human saphenous vein graft preservation: preliminary anatomic report. Eur J Cardiothorac Surg. 1993;7(10):548-52.</citation>
    <PMID>8267997</PMID>
  </reference>
  <reference>
    <citation>Winkler B, Reineke D, Heinisch PP, Schönhoff F, Huber C, Kadner A, Englberger L, Carrel T. Graft preservation solutions in cardiovascular surgery. Interact Cardiovasc Thorac Surg. 2016 Aug;23(2):300-9. doi: 10.1093/icvts/ivw056. Epub 2016 Apr 10. Review.</citation>
    <PMID>27068248</PMID>
  </reference>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>October 4, 2020</study_first_submitted>
  <study_first_submitted_qc>October 28, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 3, 2020</study_first_posted>
  <last_update_submitted>October 28, 2020</last_update_submitted>
  <last_update_submitted_qc>October 28, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 3, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Klinikum Floridsdorf</investigator_affiliation>
    <investigator_full_name>Bernhard Winkler, Associate Professor Priv. Doz. DDR.</investigator_full_name>
    <investigator_title>Associate Professor MD</investigator_title>
  </responsible_party>
  <keyword>vein</keyword>
  <keyword>preservation</keyword>
  <keyword>endothelium</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>only during publication or manuscript preparation data will be shared but no patients names or data.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

